ArticleEuropean journal of immunology2010
DC expressing transgene Foxp3 are regulatory APC.
Article in European journal of immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Abrogation and homeostatic restoration of IgE responses by a universal IgE allergy CTL vaccine-The three signal self/non-self/self (S/NS/S) theory.Immunology · 2024Article
- Mass Cytometry Reveals the Imbalanced Immune State in the Peripheral Blood of Patients with Essential Hypertension.Cardiovascular therapeutics · 2023Article
- Elevated Foxp3Frontiers in immunology · 2022Article
- Potential therapeutic effects of interleukin-35 on the differentiation of naïve T cells into HeliosMolecular immunology · 2021Article
- Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.Frontiers in immunology · 2021Review
- Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution.PloS one · 2019Article
- Article
- FoxP3 Expression in Macrophages, Cancer, and B Cells-Is It Real?Clinical reviews in allergy & immunology · 2017Review
- Effects of Foxp3 gene modified dendritic cells on mouse corneal allograft rejection.International journal of clinical and experimental medicine · 2015Article
- Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.International journal of molecular sciences · 2014Article
- Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.Immunological investigations · 2012Review
- Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?Journal of immunotherapy (Hagerstown, Md. : 1997) · 2011Article
- Allogeneic apoptotic thymocyte-stimulated dendritic cells expand functional regulatory T cells.Immunology · 2011Article
- STAT6 expression in multiple cell types mediates the cooperative development of allergic airway disease.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog.Immunology · 2011Article
- Lineage-specific transcription factors in unexpected places.European journal of immunology · 2010Article
- How tolerogenic dendritic cells induce regulatory T cells.Advances in immunology · 2010Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Tolerogenic DC and suppressive Foxp3(+) Treg play important roles in preventing autoimmunity and allograft rejection. We report that (adenovirus mediated) ectopic expression of Foxp3 in human DC (i.e. DC.Foxp3) yields an APC that severely limits T-cell proliferation and type-1 immune responses from the naïve, but not memory, pool of responder T cells in vitro. In marked contrast, the frequencies of type-2 and Treg responses were dramatically increased after stimulation of naïve T cells with DC.Foxp3 versus control DC. DC.Foxp3-induced CD4(+)CD25(+) Treg cells potently suppressed the proliferation of, and IFN-gamma production from, CD4(+) and CD8(+) responder T cells. Notably, the immunosuppressive biology of DC.Foxp3 was effectively normalized by addition of 1-methyl-tryptophan or neutralizing anti-TGF-beta1 Ab during the period of T-cell priming. These data suggest the potential utility of regulatory DC.Foxp3 and/or DC.Foxp3-induced CD4(+)CD25(+) Treg as translational agents for the amelioration or prevention of pathology in the setting of allograft transplantation and/or autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.